🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Forodesine 200 mg

    Biocryst

    Cutaneous T-cell Lymphoma (CTCL),

    phase 2 small molecule completed

    1 trial

  2. Forodesine Hydrochloride Sterile Solution, 5 mg/mL

    Biocryst

    Leukemia

    phase 2 small molecule terminated

    1 trial

  3. Full Spectrum Microbiota

    Finch Therapeutics Group

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule completed

    1 trial

  4. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  5. G-202

    BRIGHT MINDS BIOSCIENCES INC.

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  6. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  7. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  8. G-Pen(TM) 1 mg

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  9. G-Pump™ (glucagon infusion)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  10. GLPG0259 oral capsule

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  11. GLPG0634

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  12. GLPG0634

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    4 trials

  13. GLPG0974

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  14. GLPG1205

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  15. GLPG1205

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  16. GLPG1690

    Lakefront Biotherapeutics NV

    Systemic Sclerosis

    phase 2 small molecule terminated

    2 trials

  17. GLPG1690 600 mg QD

    Lakefront Biotherapeutics NV

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  18. GLPG1837 dose 1

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  19. GLPG1972

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  20. GLPG2222 150 mg q.d.

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  21. GLPG2222 50 mg

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  22. GLPG2737

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  23. GLPG2737

    Lakefront Biotherapeutics NV

    Autosomal Dominant Polycystic Kidney Disease

    phase 2 small molecule terminated

    1 trial

  24. GLPG3667

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources